Armata Pharmaceuticals (ARMP) Financials

Armata Pharmaceuticals, Inc. (ARMP) recorded an outflow of $26.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Armata Pharmaceuticals, Inc. (ARMP) recorded an outflow of $25.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Armata Pharmaceuticals, Inc. (ARMP) had $76.9M in total assets as of fiscal year 2025, including both current and long-term assets.

Armata Pharmaceuticals, Inc. (ARMP) invested $542K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Armata Pharmaceuticals, Inc. (ARMP) invested $23.7M in research and development during fiscal year 2025.

Armata Pharmaceuticals, Inc. (ARMP) had 37M shares outstanding as of fiscal year 2025.

Armata Pharmaceuticals, Inc. (ARMP) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.

Armata Pharmaceuticals, Inc. (ARMP) had a return on assets of -226.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Armata Pharmaceuticals, Inc. (ARMP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $129.8M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Armata Pharmaceuticals, Inc. (ARMP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $129.8M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Armata Pharmaceuticals, Inc. (ARMP) held $8.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.8M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Armata Pharmaceuticals, Inc. (ARMP) has negative shareholder equity of -$218.6M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Armata Pharmaceuticals, Inc. (ARMP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Armata Pharmaceuticals, Inc. (ARMP) reported a net loss of $173.8M while operations used $25.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.